Recent Insights into the Management of Behçet Syndrome
Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, D...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-07-01
|
Series: | Journal of Inflammation Research |
Subjects: | |
Online Access: | https://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIR |
id |
doaj-634233baf6474120be18e3672eced3ae |
---|---|
record_format |
Article |
spelling |
doaj-634233baf6474120be18e3672eced3ae2021-07-25T19:23:41ZengDove Medical PressJournal of Inflammation Research1178-70312021-07-01Volume 143429344167103Recent Insights into the Management of Behçet SyndromeOzguler YOzdede AHatemi GYesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitorhttps://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIRbehçet syndrometreatmentmanagementbiologic agentstnf inhibitor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ozguler Y Ozdede A Hatemi G |
spellingShingle |
Ozguler Y Ozdede A Hatemi G Recent Insights into the Management of Behçet Syndrome Journal of Inflammation Research behçet syndrome treatment management biologic agents tnf inhibitor |
author_facet |
Ozguler Y Ozdede A Hatemi G |
author_sort |
Ozguler Y |
title |
Recent Insights into the Management of Behçet Syndrome |
title_short |
Recent Insights into the Management of Behçet Syndrome |
title_full |
Recent Insights into the Management of Behçet Syndrome |
title_fullStr |
Recent Insights into the Management of Behçet Syndrome |
title_full_unstemmed |
Recent Insights into the Management of Behçet Syndrome |
title_sort |
recent insights into the management of behçet syndrome |
publisher |
Dove Medical Press |
series |
Journal of Inflammation Research |
issn |
1178-7031 |
publishDate |
2021-07-01 |
description |
Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitor |
topic |
behçet syndrome treatment management biologic agents tnf inhibitor |
url |
https://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIR |
work_keys_str_mv |
AT ozgulery recentinsightsintothemanagementofbehccediletsyndrome AT ozdedea recentinsightsintothemanagementofbehccediletsyndrome AT hatemig recentinsightsintothemanagementofbehccediletsyndrome |
_version_ |
1721282529815691264 |